MAPT and Alzheimer disease: Thus, while it is important to note here that this extensively used mouse model of AD is unique among many to recapitulate Aβ and tau-driven neurotoxicity found in human tissue or imaging experiments, and vice versa, successful therapies developed and tested have been universally unsuccessful in human clinical trials, prompting a reassessment of the development, use and interpretations of the data acquired from such models [133].